Durability score
60/100
Valuation score
28/100
Momentum score
54.3/100
Market Capitalizati...
2748.0
AVG Broker Target
270
PE TTM Price to Ear...
17.4
Suven Life Sciences Ltd.    
18 Jul 2018, 12:51PM
215.90
-2.04%
Statement Of Investor Complaints For The Quarter Ended June 2018
BSE India
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 036360 Name of the Signatory :- K. Hanumantha RaoDesignation :- Company Secretary and Compliance Officer
Suven Life Sciences Ltd.    
17 Jul 2018
215.90
-2.04%
Suven Life Sciences Ltd.    
16 Jul 2018
215.90
-2.04%
Suven Life Sciences Ltd.    
04 Jul 2018
215.90
-2.04%
Business Standard
These patents are valid through 2031, 2034, 2034 and 2036 respectively, the company said in a BSE filing
Suven Life Sciences Ltd.    
04 Jul 2018
215.90
-2.04%
Suven Life Sciences Ltd.    
25 Jun 2018
215.90
-2.04%
Suven Life Sciences Ltd.    
12 Jun 2018
215.90
-2.04%
Business Line
Suven Life Sciences today said it has been granted a product patent by China and the US each for a new chemical entity (NCE) for treatment of disord
Suven Life Sciences Ltd. is trading above it's 200 day SMA of 196.45
Suven Life Sciences Ltd.    
12 Jun 2018
215.90
-2.04%
Suven Life Sciences Ltd.    
08 Jun 2018
215.90
-2.04%
default
Suven Life Sciences Ltd.    
08 Jun 2018
215.90
-2.04%
Emkay
Suven Life Sciences (SVLS) is a compelling play on the recovery being witnessed in global R&D; spending, as reflected in strong fund raising by biotech start-ups as well as a fastgrowing research pipeline across multiple stages of clinical trials. Also, the global Clinical Development & Manufacturing Organizations (CDMO) industry has undergone significant consolidation, both at the Clinical Research Organizations (CRO) level as well as at the API manufacturing level. As a result, fewer and only niche players are left in both clinical services and API manufacturing. SVLS enjoys a strong margin profile with EBITDA margin of 30%+. Earnings CAGR over FY18-20E is estimated at 19% and ROIC of 28%. We initiate coverage on SVLS with a...
Suven Life Sciences Ltd.'s price crossed below SMA30 today
  • Stock Price (222.20) crossed above 30 Day SMA (217.18) on 17 July, 2018
  • Emkay released a Buy report for Suven Life Sciences Limited with a price target of 270.0 on 08 Jun, 2018.
  • Month Change by 25.72% (Crossed threshold 20%) on 11 June, 2018
  • Week Change by 21.47% (Crossed threshold 20%) on 11 June, 2018
  • Stock Price (202.80) crossed above 150 Day SMA (191.68) on 07 June, 2018
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
Feb. 8, 20171.00INTERIM-
March 14, 20161.00SPECIAL-
March 14, 20161.00INTERIM-
July 23, 20150.60--
July 24, 20142.00SPECIAL-
All dividends by SUVEN
Ex-Date Dividend Bonus Ratio Record Date
March 23, 20071:1April 2, 2007
All bonuses by SUVEN